A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ENGASERTIB IN SUBJECTS WITH MODERATE TO SEVERE HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)

Registry ID

HHT-301

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

VADERIS THERAPEUTICS AG

Last update

2026-06-18

Conditions

• HEREDITARY HAEMORRHAGIC TELANGIECTASIA

Related clinical trials

• A PHASE 1/2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 2-PART STUDY OF THE SAFETY, TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE DOSE ALN-6400 IN ADULT HEALTHY VOLUNTEERS AND MULTIPLE DOSE ALN-6400 IN ADULT PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
• DOXYCYCLINE CROSSOVER TRIAL FOR HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)

View on source registry